Recombinant infectious bovine rhinotracheitis virus

• US 5,874,279 A
• Filed: 11/03/1994
• Issued: 02/23/1999
• Est. Priority Date: 07/18/1991
• Status: Expired due to Term

• Current Assignee: Syntro Corp. (Mallinckrodt plc)
• Original Assignee: Syntro Corp. (Mallinckrodt plc)
• Inventors: Cochran, Mark D., Macdonald, Richard D.
• Primary Examiner(s): KETTER, JAMES S
• Application Number:
  US08/185,949
• Time in Patent Office: 1,573 Days
• Field of Search: 435/320.1, 435/235.1, 435/172.1, 435/172.3, 424/93.2, 536/23.72
• US Class Current: 435/235.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/16743 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovines from diseases particular to them, including infectious bovine rhinotracheitis and bovine respiratory disease complex. The present invention further provides methods for distinguishing an animal vaccinated with a vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein, the gpG glycoprotein, and US2 genes of an IBR virus. The present invention further provides homology vectors for producing recombinant IBR viruses.

Claims

1. A live recombinant infectious bovine rhinotracheitis virus comprising a first and a second foreign DNA, each of which encodes a polypeptide of a RNA virus, inserted into an infectious bovine rhinotracheitis virus genome, wherein the first and the second foreign DNA are inserted into a non-essential region of the infectious bovine rhinotracheitis virus genome, which region is the same or different and is selected from the group consisting of the glycoprotein E(gpE) gene, the glycoprotein G(gpG) gene and the US2 gene.

2. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising a deletion within the US2 gene of the infectious bovine rhinotracheitis virus genome.

3. The live recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the first and second foreign DNA sequences are inserted within the glycoprotein E(gE) gene of the infectious bovine rhinotracheitis virus genome.

4. The live recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA encodes a detectable marker.

5. The live recombinant infectious bovine rhinotracheitis virus of claim 4, wherein the detectable marker is E. coli β

-galactosidase or E. coli β

-glucoronidase.

6. The live recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA encodes a polypeptide which is antigenic.

7. The live recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA encodes a polypeptide which is selected from a group consisting of Bovine Respiratory Syncytial Virus fusion protein, Bovine Respiratory Syncytial Virus attachment protein, Bovine Respiratory Syncytial Virus nucleocapsid protein, Parainfluenza type 3 fusion protein, Bovine Viral Diarrhea Virus glycoprotein 53, and P Haemolytica Leukotoxin.